FDA’s advisory panel: Why so few agency people?
As reported in PRWeek back in June, the Food and Drug Administration has gone ahead and formed an advisory panel to advise the agency on risk communication. Here’s who they’ve settled on. Thanks to Pharmalot for pointing out the release of the list.
The interesting name on that list, from PRWeek’s perspective, is AnnaMaria DeSalva, worldwide director of healthcare for Hill and Knowlton. Most of the list looks to be made up of academics, which leads me to wonder why DeSalva is the only one from the agency world on the panel. If there is a difference of opinion coming from within the agency world on how the FDA could better communicate risk (which is what I hear over and over again) why isn’t there a couple more familiar names on the list?
